Cargando…

Elevated BCRP/ABCG2 Expression Confers Acquired Resistance to Gefitinib in Wild-Type EGFR-Expressing Cells

BACKGROUND: The sensitivity of non-small cell lung cancer (NSCLC) patients to EGFR tyrosine kinase inhibitors (TKIs) is strongly associated with activating EGFR mutations. Although not as sensitive as patients harboring these mutations, some patients with wild-type EGFR (wtEGFR) remain responsive to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Yun-Ju, Huang, Wei-Chien, Wei, Ya-Ling, Hsu, Sheng-Chieh, Yuan, Ping, Lin, Heather Y., Wistuba, Ignacio I., Lee, J. Jack, Yen, Chia-Jui, Su, Wu-Chou, Chang, Kwang-Yu, Chang, Wen-Chang, Chou, Tse-Chuan, Chou, Chao-Kai, Tsai, Chang-Hai, Hung, Mien-Chie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3121773/ https://www.ncbi.nlm.nih.gov/pubmed/21731744 http://dx.doi.org/10.1371/journal.pone.0021428

Ejemplares similares

Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines
por: Galetti, Maricla, et al.
Publicado: (2015)

BCRP/ABCG2 in the Placenta: Expression, Function and Regulation
por: Mao, Qingcheng
Publicado: (2008)

BCRP/ABCG2 in the Placenta: Expression, Function and Regulation
por: Mao, Qingcheng
Publicado: (2008)

Impact of cellular folate status and epidermal growth factor receptor expression on BCRP/ABCG2-mediated resistance to gefitinib and erlotinib
por: Lemos, C, et al.
Publicado: (2009)

Expression of ABCG2 (BCRP) in mouse models with enhanced erythropoiesis
por: Latunde-Dada, Gladys O., et al.
Publicado: (2014)

BCRP/ABCG2 Inhibition Sensitizes Hepatocellular Carcinoma Cells to Sorafenib
por: Huang, Wei-Chien, et al.
Publicado: (2013)

Chicken xenobiotic receptor upregulates the BCRP/ABCG2 transporter
por: Xu, Ziyong, et al.
Publicado: (2022)

Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics
por: Noguchi, Kohji, et al.
Publicado: (2014)

Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
por: Gow, Chien-Hung, et al.
Publicado: (2005)

Effects of α-Adrenoceptor Antagonists on ABCG2/BCRP-Mediated Resistance and Transport
por: Takara, Kohji, et al.
Publicado: (2012)

Gene and functional up-regulation of the BCRP/ABCG2 transporter in hepatocellular carcinoma
por: Sukowati, Caecilia HC, et al.
Publicado: (2012)

New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies
por: Westover, David, et al.
Publicado: (2015)

Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression
por: Nakanishi, Takeo, et al.
Publicado: (2012)

In Silico Prediction of Inhibition of Promiscuous Breast Cancer Resistance Protein (BCRP/ABCG2)
por: Ding, Yi-Lung, et al.
Publicado: (2014)

Development of precision medicine approaches based on inter-individual variability of BCRP/ABCG2
por: Chen, Liming, et al.
Publicado: (2019)

The salvage therapy in lung adenocarcinoma initially harbored susceptible EGFR mutation and acquired resistance occurred to the first-line gefitinib and second-line cytotoxic chemotherapy
por: Yang, Chih-Jen, et al.
Publicado: (2017)

Extracellular Vesicle miR-200c Enhances Gefitinib Sensitivity in Heterogeneous EGFR-Mutant NSCLC
por: Lin, Chien-Chung, et al.
Publicado: (2021)

Extra-Renal Elimination of Uric Acid via Intestinal Efflux Transporter BCRP/ABCG2
por: Hosomi, Atsushi, et al.
Publicado: (2012)

Modulating Drug Resistance by Targeting BCRP/ABCG2 Using Retrovirus-Mediated RNA Interference
por: Xie, Ni, et al.
Publicado: (2014)

Correction: Modulating Drug Resistance by Targeting BCRP/ABCG2 Using Retrovirus-Mediated RNA Interference
Publicado: (2014)

Genistein and Glyceollin Effects on ABCC2 (MRP2) and ABCG2 (BCRP) in Caco-2 Cells
por: Schexnayder, Chandler, et al.
Publicado: (2015)

Interactions of ABCG2 (BCRP) with epidermal growth factor receptor kinase inhibitors developed for molecular imaging
por: Qawasmi, Israa, et al.
Publicado: (2014)

Jump into a New Fold—A Homology Based Model for the ABCG2/BCRP Multidrug Transporter
por: László, Laura, et al.
Publicado: (2016)

ABCG2/BCRP transport mechanism revealed through kinetically excited targeted molecular dynamics simulations
por: Dudas, B., et al.
Publicado: (2022)

ABCG2 contributes to the development of gout and hyperuricemia in a genome-wide association study
por: Chen, Chung-Jen, et al.
Publicado: (2018)

The inhibition of ABCB1/MDR1 or ABCG2/BCRP enables doxorubicin to eliminate liver cancer stem cells
por: Yin, Wang, et al.
Publicado: (2021)

BCRP expression in schwannoma, plexiform neurofibroma and MPNST
por: de Vries, Maurits, et al.
Publicado: (2017)

NFE2L2/NRF2 silencing-inducible miR-206 targets c-MET/EGFR and suppresses BCRP/ABCG2 in cancer cells
por: Choi, Bo-Hyun, et al.
Publicado: (2017)

Breast cancer resistance protein (Bcrp/Abcg2) is selectively modulated by lipopolysaccharide (LPS) in the mouse yolk sac
por: Martinelli, L.M., et al.
Publicado: (2020)

Tetrahydroquinoline/4,5‐Dihydroisoxazole Molecular Hybrids as Inhibitors of Breast Cancer Resistance Protein (BCRP/ABCG2)
por: Vesga, Luis C., et al.
Publicado: (2021)

Clinical Significance of ABCG2/BCRP Quantified by Fluorescent Nanoparticles in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
por: Tada, Hiroshi, et al.
Publicado: (2023)

Co-delivery of Gefitinib and chloroquine by chitosan nanoparticles for overcoming the drug acquired resistance
por: Zhao, Liang, et al.
Publicado: (2015)

Targeting the EGFR/PCNA Signaling Suppresses Tumor Growth of Triple-Negative Breast Cancer Cells with Cell-Penetrating PCNA Peptides
por: Yu, Yung-Luen, et al.
Publicado: (2013)

A comprehensive analysis of the association of common variants of ABCG2 with gout
por: Yu, Kuang-Hui, et al.
Publicado: (2017)

The Pyrazolo[3,4-d]pyrimidine Derivative, SCO-201, Reverses Multidrug Resistance Mediated by ABCG2/BCRP
por: Ambjørner, Sophie E. B., et al.
Publicado: (2020)

Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
por: Li, Yang-Ling, et al.
Publicado: (2018)

EGFR Tyrosine Kinase Inhibitor Efficacy in Older Adult Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer: A Meta-Analysis and Systematic Review
por: Chen, Chang-Hung, et al.
Publicado: (2022)

Enhancement of gefitinib-induced growth inhibition by Marsdenia tenacissima extract in non-small cell lung cancer cells expressing wild or mutant EGFR
por: Han, Shu-Yan, et al.
Publicado: (2014)

PTEN Regulates BCRP/ABCG2 and the Side Population through the PI3K/Akt Pathway in Chronic Myeloid Leukemia
por: Huang, Fang-Fang, et al.
Publicado: (2014)

Breast Cancer Resistance Protein (BCRP/ABCG2) Inhibits Extra Villous Trophoblast Migration: The Impact of Bacterial and Viral Infection
por: Lye, Phetcharawan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_esl98e0qqeuo3paitokpupm5bn